Bessemer Group
SRPT icon

Bessemer Group’s Sarepta Therapeutics SRPT Stock Holding History

Bessemer Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4K Sell
199
-535
-73% -$10.1K ﹤0.01% 2325
2026
Q1 		$16K Buy
734
+583
+386% +$11.3K ﹤0.01% 1995
2025
Q4 		$3K Buy
151
+136
+907% +$2.87K ﹤0.01% 2371
2025
Q3 		$0 Sell
15
-341
-96% -$6.08K ﹤0.01% 2716
2025
Q2 		$6K Buy
356
+127
+55% +$5.42K ﹤0.01% 1987
2025
Q1 		$15K Buy
229
+54
+31% +$5.68K ﹤0.01% 1632
2024
Q4 		$21K Buy
175
+113
+182% +$13.8K ﹤0.01% 1511
2024
Q3 		$8K Buy
+62
New +$8.57K ﹤0.01% 1764
2022
Q3 		– Sell
-11
Closed -$1K – 2157
2022
Q2 		$1K Sell
11
-88
-89% -$6.47K ﹤0.01% 1835
2022
Q1 		$8K Hold
99
– – ﹤0.01% 1438
2021
Q4 		$9K Hold
99
– – ﹤0.01% 1453
2021
Q3 		$9K Sell
99
-5
-5% -$385 ﹤0.01% 1417
2021
Q2 		$8K Hold
104
– – ﹤0.01% 1380
2021
Q1 		$8K Buy
104
+97
+1,386% +$8.95K ﹤0.01% 1350
2020
Q4 		$2K Sell
7
-34
-83% -$5.04K ﹤0.01% 1433
2020
Q3 		$6K Sell
41
-241,062
-100% -$36.6M ﹤0.01% 1179
2020
Q2 		$38.7M Buy
241,103
+7
+0% +$953 0.12% 153
2020
Q1 		$23.6M Hold
241,096
– – 0.1% 167
2019
Q4 		$31.1M Buy
+241,096
New +$24.3M 0.1% 177
2019
Q3 		– Sell
-218,644
Closed -$33.2M – 1821
2019
Q2 		$33.2M Buy
218,644
+218,587
+383,486% +$26.6M 0.11% 175
2019
Q1 		$7K Sell
57
-1,609
-97% -$207K ﹤0.01% 1553
2018
Q4 		$183K Buy
1,666
+1,643
+7,143% +$205K ﹤0.01% 1001
2018
Q3 		$4K Buy
+23
New +$3.14K ﹤0.01% 1720
2018
Q1 		– Sell
-1,000
Closed -$56K – 1785
2017
Q4 		$56K Buy
+1,000
New +$53K ﹤0.01% 1239

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Bessemer Group's SRPT Position: Q2 2026 in Review

Bessemer Group reduced its Sarepta Therapeutics (SRPT) stake by 73% in Q2 2026, selling an estimated $10.1K and leaving 199 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #2325.

Bessemer Group first reported a position in SRPT in Q4 2017 and has held it in 24 quarters since. The position peaked at $38.7M in Q2 2020. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Bessemer Group held 199 shares of Sarepta Therapeutics worth $4K as of Q2 2026.
  • Bessemer Group sold 535 Sarepta Therapeutics shares in Q2 2026, an estimated $10.1K.
  • Sarepta Therapeutics made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #2325 holding.
  • Bessemer Group first reported a position in Sarepta Therapeutics in Q4 2017 and has held it in 24 quarters since.
  • Bessemer Group's Sarepta Therapeutics position peaked at $38.7M in Q2 2020.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.